Abstracts Archive - Page 952 of 2425 - ACR Meeting Abstracts

Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto¹, Negin Shojaee ¹, Ravi Shankar P Singh ¹, Zorayr Manukyan ², Jessica Mancuso ¹, Elena Peeva ¹, Michael Vincent ¹ and Jean Beebe ¹, ¹Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, ²Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
Abstract Number: 2910 • 2019 ACR/ARP Annual Meeting
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Tianrun Cai¹, Fiona Cai ², Kumar Dahal ³, Chuan Hong ⁴ and Katherine Liao ¹, ¹Brigham and Women's Hospital, Boston, ²Stuyvesant High School, New York, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial. Billing codes from electronic health record (EHR) data are commonly used…
Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Frances humby ¹, Maya H. Buch ², Patrick Durez ³, Myles Lewis ¹, Michele Bombardieri ¹, Hasan Rizvi ⁴, Stephen Kelly ⁴, Liliane Fosatti ¹, Rebecca Hands ¹, Giovanni Giorli ¹, Arti Mahto ¹, Carlomaurizio Montecucco ⁵, Bernard Lauwerys ⁶, Vasco Romao ⁷, Arthur Pratt ⁸, Serena Bugatti ⁹, Nora Ng ¹⁰, Felice Rivellese ¹, Pauline Ho ¹¹, Mattia Bellan ¹², Mattia Congia ¹³, Patrick Verschueren ¹⁴, Pier Paolo Sainaghi ¹², Nagui Gendi ¹⁵, Bhaskar Dasgupta ¹⁶, Alberto Cauli ¹⁷, Piero Reynolds ¹⁸, Juan Cañete ¹⁹, Robert J. Moots ²⁰, Peter Taylor ²¹, Christopher Edwards ²², John Isaacs ⁸, Peter Sasieni ²³, João Eurico Fonseca ²⁴, Ernest Choy ²⁵ and Costantino Pitzalis²⁶, ¹Queen Mary University of London, London, United Kingdom, ²University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁶University of Louvain, Louvain, Belgium, ⁷University of Lisbon, Lisbon, Portugal, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹University of Pavia, Pavia, Italy, ¹⁰Guys and St Thomas NHS Trust, London, United Kingdom, ¹¹University of Manchester, Manchester, United Kingdom, ¹²University of Novara, Novara, Italy, ¹³University of Cagliari, Cagliari, Italy, ¹⁴University of Leuven, Leuven, Belgium, ¹⁵Basildon Hospital NHS Trust, Basildon, United Kingdom, ¹⁶Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ¹⁷Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, ¹⁸Homerton University NHS Trust, London, United Kingdom, ¹⁹Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ²⁰Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ²¹University of Oxford, Oxford, United Kingdom, ²²University of Southampton, Southampton, United Kingdom, ²³Kings College London, London, United Kingdom, ²⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ²⁵Cardiff University School of Medicine, Cardiff, United Kingdom, ²⁶Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
Abstract Number: 2912 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study
Sandra van Bijnen ¹, Maaike Boonstra ², Els van den Ende ³, Lucia Kroft ², Bram Geurts ¹, Miranda Snoeren ¹, Anne Schouffoer ², Julia Spierings ⁴, Jacob van Laar ⁵, Thomas Huizinga ⁶, Alexandre Voskuyl ⁷, Walter van der Velden ¹, Frank van den Hoogen ³, Jeska de Vries-Bouwstra ⁶ and Madelon Vonk⁸, ¹Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³Department of Rheumatology, Radboud University Medical Center, Nijmegen, Gelderland, Netherlands, ⁴Utrecht Medical Centre, Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Amsterdam Univiversity Medical Centre, Amsterdam, Noord-Holland, Netherlands, ⁸Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands
Background/Purpose: Autologous hematopoietic stemcell transplantation (HSCT) has shown to improve survival of SSc patients with poor prognosis, but is hampered by treatment related mortality (TRM).…
Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 2914 • 2019 ACR/ARP Annual Meeting
Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)
Silvia Bellando-Randone¹, Gemma Lepri ¹, Dorte Huscher ², Tunde Minier ³, Serena Guiducci ⁴, Cosimo Bruni ¹, Laszlo Czirjak ³, Maurizio Cutolo ⁵, Vanessa Smith ⁶, Jerome Avouac ⁷, Daniel Furst ⁸, Yannick Allanore ⁷, Oliver Distler ⁹ and Marco Matucci-Cerinic ¹⁰, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Charitè-Universitaetsmedizin Berlin, Berlin, Germany, ³University of Pecs, Pecs, Hungary, ⁴Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁶Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁷Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁸University of California, Los Angeles, CA, ⁹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ¹⁰University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: The very early diagnosis of SSc is a challenge today. The aim of the VEDOSS project was to study in an at-risk population, the…
Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Bhaven Mehta ¹, Jennifer Franks ¹, Yiwei Yuan ², Yue Wang ¹, Veronica Berrocal ³, Tammara Wood ¹, Cathie Spino ⁴, David Fox ⁵, Dinesh Khanna ⁶ and Michael Whitfield⁷, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Hanover, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Ann Arbor, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁷Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH
Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…
Abstract Number: 2916 • 2019 ACR/ARP Annual Meeting
Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
Pravitt Gourh ¹, Sarah Safran², Steven Boyden ³, Ami Shah ⁴, Maureen Mayes ⁵, Ayo Doumatey ⁶, Amy Bentley ⁶, Daniel Shriner ⁶, Robyn Domsic ⁷, Thomas Medsger Jr ⁸, Paula Ramos ⁹, Richard Silver ¹⁰, Virginia Steen ¹¹, John Varga ¹², Vivien Hsu ¹³, Lesley Saketkoo ¹⁴, Elena Schiopu ¹⁵, Dinesh Khanna ¹⁶, Jessica Gordon ¹⁷, Brynn Kron ¹⁸, Lindsey Criswell ¹⁹, Heather Gladue ²⁰, Chris Derk ²¹, Elana Bernstein ²², S Louis Bridges ²³, Victoria Shanmugam ²⁴, Kathleen Kolstad ²⁵, Lorinda Chung ²⁶, Suzanne Kafaja ²⁷, Reem Jan ²⁸, Marcin Trojanowski ²⁹, Avram Goldberg ³⁰, Benjamin Korman ³¹, Peter Steinbach ³², Settara Chandrasekharappa ⁶, James Mullikin ⁶, Adebowale Adeyemo ⁶, Charles Rotimi ⁶, Frederick Wigley ³³, Daniel Kastner ³⁴, Francesco Boin ³⁵, Elaine Remmers ⁶ and Theresa Alexander ³⁶, ¹National Institutes of Rheumatology, Bethesda, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, MD, ³University of Utah, SALT LAKE CITY, UT, ⁴Johns Hopkins Hospital, Baltimore, MD, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶National Human Genome Research Institute (NHGRI), Bethesda, MD, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburg School of Medicine, Pittsburg, PA, ⁹Medical University of South Carolina, Charleston, ¹⁰Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹¹Georgetown University, Washington, D.C., USA, Georgetown, ¹²Northwestern University, Chicago,, IL, ¹³Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ¹⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ¹⁵Department of Rheumatology, University of Michigan, Ann Arbor, ¹⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹⁷Hospital for Special Surgery, New York, NY, ¹⁸University of California San Francisco, San Francisco, CA, ¹⁹University of California, San Francisco, San Francisco, ²⁰Arthritis & Osteoporosis Consultants Of The Carolinas, Charlotte, NC, ²¹University of Pennsylvania, Philadelphia, PA, ²²Division of Rheumatology, Columbia University, New York, NY, ²³University of Alabama at Birmingham, Birmingham, ²⁴George Washington University, Georgetown, DC, ²⁵Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, ²⁶Stanford University, Palo Alto, CA, ²⁷Department of Medicine. Rheumatology Division. UCLA, Los Angeles, CA, ²⁸University of Chicago Pritzker School of Medicine, Chicago, IL, ²⁹Boston University Medical Center, Boston, MA, ³⁰New York University Langone Medical Center, New York, NY, ³¹University of Rochester Medical Center, Rochester, NY, ³²Center for Molecular Modeling, Center for Information Technology, National Institutes of Health, Bethesda, MD, ³³Johns Hopkins University, Division of Rheumatology, Baltimore, ³⁴National Institutes of Health, Bethesda, MD, ³⁵UCSF, San Francisco, CA, ³⁶University of Maryland, College Park, MD
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a heterogeneous disease that is divided into limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms based on the…
Abstract Number: 2917 • 2019 ACR/ARP Annual Meeting
Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Alicia Rodriguez-Pla¹ and Robert W Simms ², ¹University of Arizona/Banner Health Medical Center, Tucson, AZ, ²Boston University, Boston, MA
Background/Purpose: Population mortality studies in the United States have previously reported a progressive increase in the scleroderma (SSc) mortality rates from 1959 to 2002. Identification…
Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting
Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Mitsuhiro Akiyama ¹, Hui Zhang ¹, Ryu Watanabe ¹, Toshihisa Maeda ², Gerald Berry ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA, ²Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…
Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting
Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Tomoyuki Mutoh¹, Tsuyoshi Shirai ¹, Tomonori Ishii ², Yuko Shirota ³, Hideo Harigae ¹ and Hiroshi Fujii ¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Hospital, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…
Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting
Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, David Cuthbertson ⁴, Simon Carette ⁵, Gary S. Hoffman ⁶, Nader A. Khalidi ⁷, Curry L. Koening ⁸, Carol Langford ⁹, Kathleen Maksimowicz-McKinnon ¹⁰, Carol A. McAlear ¹¹, Paul Monach ¹², Larry Moreland ¹³, Christian Pagnoux ¹⁴, Kaitlin Quinn ¹⁵, Joanna Robson ¹⁶, Philip Seo ¹⁷, Antoine Sreih ¹⁸, Ravi Suppiah ¹⁹, Kenneth Warrington ²⁰, Steven Ytterberg ²¹, Raashid Luqmani ³, Richard Watts ²², Peter Merkel ¹⁸ and Peter C. Grayson ²³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Utah Hospital, Salt Lake City, UT, ⁹Cleveland Clinic, Cleveland, OH, ¹⁰Henry Ford Hospital, Wayne State University, Detroit, MI, ¹¹University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University of Pittsburgh, PITTSBURGH, PA, ¹⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁵Georgetown University Hospital/National Institutes of Health, Washington, DC, ¹⁶Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹⁷Johns Hopkins Medicine, Baltimore, MD, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ²⁰Mayo Clinic Rochester, Rochester, MN, ²¹Mayo Clinic College of Medicine, Rochester, MN, ²²Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ²³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
Abstract Number: 2921 • 2019 ACR/ARP Annual Meeting
High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis
Christine rodriguez ¹, Wagih Ben Hassen ¹, Pierre Seners ², Catherine Oppenheim ¹ and Alexis Régent³, ¹Département d’imagerie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ²Service de neurologie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis of large arteries affecting people older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 2922 • 2019 ACR/ARP Annual Meeting
Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis
Kaitlin Quinn¹, Joel S. Rosenblum ², Casey A. Rimland ³, K Bates Gribbons ⁴, Mark A. Ahlman ⁵ and Peter C. Grayson ⁶, ¹Georgetown University Hospital/National Institutes of Health, Washington, DC, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) is one of several imaging modalities used in the assessment of patients with large-vessel vasculitis (LVV). Conventionally PET…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].